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COST EFFECTIVENESS OF
PHARMACOLOGICAL TREATMENT VERSUS
CARE AS USUAL FOR PANIC DISORDER
AND/OR DEPRESSION DRIVEN CHEST PAIN:
PRELIMINARY RESULTS OF UNBLINDED 
DATA
Brunenberg D, Dirksen CD, Kuijpers P, Honig A
University hospital Maastricht, Maastricht, Netherlands
OBJECTIVES: Panic disorder (PD) is an anxiety disorder,
which occurs frequently in patients presenting to a First
Heart Aid (FHA) with chest pain and/or palpitations.
Although the efﬁcacy of pharmacological treatment for
PD in a psychiatric population is high, an accepted stan-
dard treatment for PD in cardiac patients is not yet avail-
able. The objective of this study was to evaluate the
cost-effectiveness of pharmacological treatment com-
pared to care as usual in patients presenting with cardiac
complaints to a FHA in whom PD was conﬁrmed.
METHODS: The design was a randomised double-blind
placebo-controlled study with an intervention group
receiving sertraline or placebo (IG; N = 62) and a care as
usual group (CAUG; N = 44). The study was performed
from the societal perspective with a time horizon of 24
weeks. Costs were calculated using cost diaries and hos-
pital data. Primary endpoint was successful treatment,
deﬁned as reduction of ≥50% of the number of panic
attacks and/or a reduction of ≥50% on the Hamilton
Depression Rating Scale (HAMD). Secondary endpoint
was health state utility, obtained by the EQ-5D, which
was used to calculate QALYs. Incremental cost-effective-
ness ratios (ICERs) were calculated for both endpoints.
Subsequently, bootstrap analyses were performed (1000
replications) to quantify the uncertainty around the
ICERs. RESULTS: Baseline characteristics were compa-
rable for both groups. A total of 67.7% of the patients
in the IG was treated successfully versus 43.2% in the
CAUG (P = .017). Mean QALY in the IG was 0.30, versus
0.29 in the CAUG. The incremental costs amounted to
€-1361.47 (-4060, –1337) in favour of the IG. CON-
CLUSIONS: Based on this preliminary analysis with
unblinded data both ICERs indicated a dominance for IG.
This was conﬁrmed by the bootstrap results, with 84.1%
and 66.7% of the cost-effectiveness pairs, based on
respectively the primary and secondary endpoints, lying
in the southeast quadrant.
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PREVALENCE AND MEDICAL CARE COSTS OF
ANXIETY DISORDERS IN THE UNITED STATES:
A NATIONAL ESTIMATE USING THE MEDICAL
EXPENDITURE PANEL SURVEY
Mychaskiw MA, Sankaranarayanan J
Purdue University, West Lafayette, IN, USA
OBJECTIVES: The objectives of this study were to deter-
mine the prevalence and direct costs of anxiety disorders
in the U.S. population. METHODS: Retrospective analy-
sis was conducted of the 1999 Medical Expenditure Panel
Survey (MEPS). The MEPS collected data from a nation-
ally representative sample of 24,618 respondents and
from respondents’ health care and insurance providers.
Data extracted for this study included medical conditions
and use and payments for medical care. Anxiety disorders
were deﬁned using the current Diagnostic and Statistical
Manual of Mental Disorders (DSM-IV-TR) and were
mapped to corresponding ICD-9-CM codes and included
anxiety and panic disorders, stress disorders, obsessive-
compulsive disorder, and phobias. Anxiety patients were
identiﬁed using ICD-9-CM codes and direct costs were
calculated using patient and third party payments for
anxiety-related medical events by type of medical care.
Sample estimates were weighted and projected to the pop-
ulation and 95% conﬁdence limits were calculated using
the Taylor expansion method. RESULTS: The prevalence
of anxiety disorders was 4.04% or 11,163,423 individu-
als (95% C.L. = 3.64%, –4.44%). Total direct costs of
anxiety disorders were $5,986,529,599. Prescription
medications and ofﬁce-based medical provider visits
accounted for the largest proportions of direct costs, at
$1,963,991,706 (mean = $58; 95% C.L. = $53, –$64)
and $1,890,703,392 (mean = $67; 95% C.L. = $55,
–$79), respectively. Inpatient stays represented
$1,237,191,177 while home health care expenses were
$708,555,879. Emergency department and outpatient
services were each below $140 million. CONCLUSIONS:
Affecting more than 11 million individuals with medical
care costs of almost $6 billion, the impact of anxiety 
disorders was substantial. Prescriptions and medical
provider visits were direct cost drivers, collectively
accounting for more than 60% of total direct costs.
However, expenditures on inpatient stays and home
health care were sizeable, together representing nearly $2
billion or one-third of total direct costs. Additional mea-
sures should be considered to enhance diagnosis and
treatment of anxiety and avert more costly medical care
alternatives.
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